Affiliation:
1. Department of Biology Edge Hill University Ormskirk UK
2. Liverpool Centre for Cardiovascular Science University of Liverpool Liverpool UK
3. UCL Great Ormond Street Institute of Child Health University College London London UK
Abstract
AbstractCandidate drugs targeting the central nervous system (CNS) demonstrate extremely low clinical success rates, with more than 98% of potential treatments being discontinued due to poor blood–brain barrier (BBB) permeability. Neurological conditions were shown to be the second leading cause of death globally in 2016, with the number of people currently affected by neurological disorders increasing rapidly. This increasing trend, along with an inability to develop BBB permeating drugs, is presenting a major hurdle in the treatment of CNS‐related disorders, like dementia. To overcome this, it is necessary to understand the structure and function of the BBB, including the transport of molecules across its interface in both healthy and pathological conditions. The use of CNS drug carriers is rapidly gaining popularity in CNS research due to their ability to target BBB transport systems. Further research and development of drug delivery vehicles could provide essential information that can be used to develop novel treatments for neurological conditions. This review discusses the BBB and its transport systems and evaluates the potential of using nanoparticle‐based delivery systems as drug carriers for CNS disease with a focus on dementia.
Funder
Academy of Medical Sciences
Wellcome Trust